Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.39 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | ADK | P55263 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117442 | 0.97 | CNR2 (0.40) | KCNH2CHRNA7HTR3ACNR2EGLN1 | |
| SCHEMBL5113312 | 0.90 | CHRNA7 (0.39) | KCNH2CHRNA7CNR2EGLN1PDE4A | |
| SCHEMBL5110025 | 0.89 | CHRNA7 (0.45) | KCNH2CHRNA7HTR3ACNR2 | |
| SCHEMBL5112996 | 0.87 | CNR2 (0.51) | KCNH2CHRNA7HTR3ACNR2EGLN1 | |
| SCHEMBL5112083 | 0.87 | KCNH2 (0.40) | KCNH2CHRNA7HTR3ACNR2EGLN1 | |
| SCHEMBL5120930 | 0.86 | KCNH2 (0.41) | KCNH2CHRNA7HTR3ACNR2 | |
| Hydrochloric Acid SCHEMBL5113977 | 0.86 | KCNH2 (0.40) | KCNH2CHRNA7HTR3ACNR2EGLN1 | |
| SCHEMBL5123021 | 0.84 | CNR2 (0.53) | KCNH2CHRNA7CNR2EGLN1PDE4A | |
| SCHEMBL5112357 | 0.82 | CHRNA7 (0.43) | KCNH2CHRNA7CNR2EGLN1PDE4A | |
| SCHEMBL5113901 | 0.81 | HTR3A (0.41) | KCNH2CHRNA7HTR3APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551843-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | claimed |
| WO-2004024729-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-03-25 | — | — | WO | claimed |
| US-7442694-B2 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1551843-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| WO-2004024729-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | DBH, CHRNA6, DDT | KCNH2 1656/4885CHRNA7 13/4885HTR3A 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.